Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-12-01T04:08:02.057Z Has data issue: false hasContentIssue false
  • English
  • Français

Molecular Regulation of Taxane-Induced Apoptosis

Published online by Cambridge University Press:  02 July 2020

K. Bhalla
K. Bhalla*
Affiliation:
Emory University School of Medicine and Winship Cancer Center, Atlanta, GA30322
Get access

Extract

Following intracellular uptake, taxanes bind to β tubulin and suppress microtubular dynamics, resulting in stable microtubule bundles and mitotic arrest of cancer cells. This proximal taxane- β tubulin interaction depends on the amount of intracellular accumulation of taxanes. Since taxanes are substrates for the membrane transporter P-glycoprotein (PGP) but not the MRP, overexpression of PGP but not MRP reduces the intracellular accumulation and cytotoxicity of taxanes. Recent reports have also suggested that alterations in the levels of specific β tubulin isotypes can reduce the effects of taxanes on microtubule dynamics, thereby inhibiting the mitotic effects and resulting cytotoxicity of taxanes.6 For example, increased βIV and (βIII tubulin levels may confer resistance against microtubule and cytostatic effects of taxanes. Taxane-induced G2/M arrest is preceded by the activation of cell-cycle mitotic kinase CDK1, which promotes the G2/M transition. Recent studies have indicated that the loss of cell-cycle Gl checkpoint due to p53 mutations may enhance taxane-induced mitotic arrest and cytotoxicity.

Type
Chemotherapeutic Agents That Affect Microtubules: Mechanisms of Response and Chemotherapeutic Agents and Microtubules
Information
Microscopy and Microanalysis , Volume 4 , Issue S2: Proceedings: Microscopy & Microanalysis '98, Microscopy Society of America 56th Annual Meeting, Microbeam Analysis Society 32nd Annual Meeting, Atlanta, Georgia July 12-16, 1998 , July 1998 , pp. 1040 - 1041
Copyright
Copyright © Microscopy Society of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Manfredi, J. J. and Horwitz, S. B.. Pharmacol. Ther. 25(1984)83.CrossRefGoogle Scholar
2.Rao, S. et al., J. Biol. Chem. 270(1995)20235.CrossRefGoogle Scholar
3. Jordan, M. A. et al., Cancer Res. 56(1996)816.Google Scholar
4.Bhalla, K. et al., Leukemia 8(1994)465.Google ScholarPubMed
5.Huang, Y. et al., Leukemia 11(1997)253.CrossRefGoogle Scholar
6.Kavallaris, M. et al., J. Clin. Invest. 100(1997)1282.CrossRefGoogle Scholar
7.Donaldson, K. L. et al., Cell Growth & Differ. 5(1994)1041.Google Scholar
8.Wahl, A. F. et al., Nature Med. 2(1996)72.CrossRefGoogle Scholar
9.Waldman, T. et al., Nature 381(1996)713.CrossRefGoogle Scholar
10.Tang, C. et al., Leukemia 8(1994)1960.Google ScholarPubMed
11.Ibrado, A.M. et al., Cell Growth & Differ. 7(1996)1087.Google Scholar
12.Ibrado, A. M. et al., Cancer Res. 57(1997)1109.Google Scholar
13.Fang, G. et al., Proc. Amer. Assoc. Cancer Res. 1998 (submitted) (abstr).Google Scholar
14.Reed., J. C.Cell 91(1997)559.CrossRefGoogle Scholar
15.Li, P. et al., Cell 91(1997)479.CrossRefGoogle Scholar
16.Haldar, S. et al., Cancer Res. 56(1996)1253.Google Scholar
17.Changetal, B. S.., EMBO J. 16(1997)968.Google Scholar
18.Haldar, S. et al., Cancer Res. 57(1997)229.Google Scholar